SDZ 51641
SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 91456-99-4
- Fòrmula: C14H20O2
- Peso molecular:220.31
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
SDZ 51641 (700 µmol/kg; p.o.; once daily; for 28 days) reduces body weight and testicular weight, while increases liver weight, in normal Sprague Dawley rats compared with the control group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague‑Dawley rats treated STZ[1]
-
Dosage:70 µmol/kg
-
Administration:p.o.; daily; 11 days
-
Result:Inhibited hepatic fatty acid oxidation, decreased β‑hydroxybutyrate levels, reduced blood glucose production, and lowered serum glucose levels, while avoiding toxic effects on peripheral tissues such as the testes.
Chemical Information
-
No. CAS 91456-99-4
-
Peso molecular 220.31
-
Fòrmula C14H20O2
-
SMILES
CC(C=C1)=CC=C1C2(C(C)(C)C)OCCO2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- SDZ 51641
- 91456-99-4
- SDZ51641
- SDZ-51641
- Drug Intermediate
- long-chain acyl dehydrogenase
- fatty acid oxidation
- STZ-induced diabetic rats
- gluconeogenesis
- Sprague Dawley rats
- testicular toxicity
- carnitine palmitoyl transferase 2
- intramitochondrial CoA
- acetyl-CoA
- non-insulin-dependent diabetes mellitus
- Inhibitor
- inhibitor
- inhibit